Business Wire

TOMTOM

31.3.2015 07:31:31 CEST | Business Wire | Pressemeddelelse

Del
New TomTom Data Reveals Rush Hour Traffic Doubles Journey Times for Commuters

TomTom (TOM2) today releases its annual Traffic Index highlighting the impact of traffic congestion in over 200 cities around the world. TomTom data reveals that traffic congestion nearly doubles journey times during the evening rush hour. In 2014, the average commuter spent an extra 100 hours a year travelling during the evening rush hour alone.

According to TomTom Traffic data, the evening rush hour is the most congested time of day. Nearly every city with the highest overall levels of congestion can expect to double their congestion level during the evening rush hour.

Commuters in Istanbul experience the worst traffic congestion overall, the evening rush hour is no exception. The average 30 minute drive in the city will take over an hour during evening rush hour, leading to an extra 125 hours wasted stuck in traffic every year. In Los Angeles, a 30 minute commute in the evening will take 54 minutes due to congestion, an extra 92 hours annually.

“TomTom’s mission is to reduce traffic congestion for everyone,” said Ralf-Peter Schaefer, VP TomTom Traffic. “Road authorities and local governments can use TomTom’s traffic data to better manage traffic flow during the rush hour. We can help businesses plan smarter working hours to help their employees avoid travelling during rush hour. And we give drivers the real-time traffic information and smart routing they need to avoid congested roads and get there faster.”

Top ten cities with the worst evening rush hour:

Rank   City   Evening Congestion Level   Overall Congestion Level   Rank   City   Evening Congestion

Level

  Overall Congestion Level
1 Istanbul 109% 58% 6 Recife 82% 45%
2 Moscow 103% 50% 7 Bucharest 82% 41%
3 Saint Petersburg 96% 44% 8 Rio de Janeiro 81% 51%
4 Mexico City 89% 55% 9 Shenzhen 81% 34%
5 Chongqing 84% 38% 10 Los Angeles 80% 39%

To find out more information on the Traffic Index please visit: www.tomtom.com/trafficindex

-ENDS-

Notes to Editors:

This year TomTom has expanded its Traffic Index to 218 cities in 36 countries. For the first time, the Index includes traffic information for China, Romania, Taiwan, Saudi Arabia, Singapore, Slovakia, and United Arab Emirates in one comprehensive report. The Traffic Index is based on data over the year of 2014.

Overall ranking of most congested cities in 2014:

1   Istanbul   58%   6   Recife   45%
2 Mexico City 55% 7 Saint Petersburg 44%
3 Rio de Janeiro 51% 8 Bucharest 41%
4 Moscow 50% 9 Warsaw 40%
5 Salvador 46% 10 Los Angeles 39%

Extended table of the top ten cities based on the evening rush hour congestion percentage:

Evening rush hour rank   City   Evening peak congestion level   Overall congestion level   World rank (based on overall congestion level   Delay per year with a 30 minute commute during the evening rush hour (hours)
1 Istanbul 109% 58% 1 125
2 Moscow 103% 50% 4 118
3 Saint Petersburg 96% 44% 7 110
4 Mexico City 89% 55% 2 102
5 Chongqing 84% 38% 12 97
6 Recife 82% 45% 6 94
7 Bucharest 82% 41% 8 94
8 Rio de Janeiro 81% 51% 3 93
9 Shenzhen 81% 34% 31 93
10 Los Angeles 80% 39% 10 92

To filter and sort a customized raking please visit www.tomtom.com/trafficindex

About TomTom

TomTom (TOM2) empowers movement. Every day millions of people around the world depend on TomTom to make smarter decisions. We design and develop innovative products that make it easy for people to keep moving towards their goals. Best known for being a global leader in navigation and mapping products, TomTom also creates GPS Sport Watches, as well as state-of-the-art fleet management solutions and industry-leading location-based products.

Our business consists of four customer-facing business units: Consumer, Automotive, Licensing and Telematics.

Founded in 1991 and headquartered in Amsterdam, we have 4,000 employees worldwide and sell our products in over 46 countries.

Contact:

Amsterdam Press Office:
Lindsay Mandeville
PR Coordinator
+31 (0)6 11 33 4292
Lindsay.mandeville@tomtom.com
or
North America Press Office:
Karen CK Drake
Communications Director
978-405-1640
Karen.drake@tomtom.com
or
Investor Relations:
Bisera Grubesic
Investor Relations Officer
+31 (0)20 757 5119
ir@tomtom.com

Link:

Multimedia Gallery

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye